The availability of natalizumab for the treatment of multiple sclerosis
has revolutionised the practice of neurology in at least one salient
way: we now spend much more time thinking about progressive multifocal
leukoencephalopathy (PML). The reasons for this increased attention are
not difficult to identify. Many patients with multiple sclerosis have
ongoing disease activity while receiving the first-line drugs interferon
beta and glatiramer acetate, and natalizumab offers a second-stage
medica …
Read More: PML risk and natalizumab: more questions than answers.